TOI vs. LFMD, FLGT, PSNL, CSTL, INNV, FTRE, EHAB, AUNA, TALK, and SBC
Should you be buying Oncology Institute stock or one of its competitors? The main competitors of Oncology Institute include LifeMD (LFMD), Fulgent Genetics (FLGT), Personalis (PSNL), Castle Biosciences (CSTL), InnovAge (INNV), Fortrea (FTRE), Enhabit (EHAB), Auna (AUNA), Talkspace (TALK), and SBC Medical Group (SBC). These companies are all part of the "healthcare" industry.
Oncology Institute vs. Its Competitors
Oncology Institute (NASDAQ:TOI) and LifeMD (NASDAQ:LFMD) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, earnings, risk, analyst recommendations, valuation and institutional ownership.
36.9% of Oncology Institute shares are held by institutional investors. Comparatively, 35.5% of LifeMD shares are held by institutional investors. 8.5% of Oncology Institute shares are held by insiders. Comparatively, 18.4% of LifeMD shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
LifeMD has a net margin of -4.58% compared to Oncology Institute's net margin of -15.38%. LifeMD's return on equity of 0.00% beat Oncology Institute's return on equity.
LifeMD has lower revenue, but higher earnings than Oncology Institute. LifeMD is trading at a lower price-to-earnings ratio than Oncology Institute, indicating that it is currently the more affordable of the two stocks.
In the previous week, LifeMD had 1 more articles in the media than Oncology Institute. MarketBeat recorded 4 mentions for LifeMD and 3 mentions for Oncology Institute. LifeMD's average media sentiment score of 0.67 beat Oncology Institute's score of 0.00 indicating that LifeMD is being referred to more favorably in the news media.
Oncology Institute has a beta of 0.02, suggesting that its stock price is 98% less volatile than the S&P 500. Comparatively, LifeMD has a beta of 2.4, suggesting that its stock price is 140% more volatile than the S&P 500.
Oncology Institute currently has a consensus price target of $7.00, suggesting a potential upside of 183.98%. LifeMD has a consensus price target of $12.00, suggesting a potential downside of 4.34%. Given Oncology Institute's higher probable upside, equities research analysts plainly believe Oncology Institute is more favorable than LifeMD.
Summary
LifeMD beats Oncology Institute on 12 of the 16 factors compared between the two stocks.
Get Oncology Institute News Delivered to You Automatically
Sign up to receive the latest news and ratings for TOI and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding TOI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Oncology Institute Competitors List
Related Companies and Tools
This page (NASDAQ:TOI) was last updated on 7/5/2025 by MarketBeat.com Staff
